Oral Combo Tx Soars in HCV

In one large international study, 99.3% of patients infected with genotype 1b receiving ABT-450/r plus ombitasvir and dasabuvir -- the direct-acting 3D regimen -- without ribavirin showed sustained virologic responses at 12 weeks (SVR12), as did 98.7% of those who were given that regimen plus ribavirin, Andreas Maieron, MD, of Elisabeth Hospital in Linz, Austria, reported during the presidential plenary session at the annual meeting of the American College of Gastroenterology. http://www.medpagetoday.com/MeetingCoverage/ACG/48161?xid=nl_mpt_DHE_2014-10-21&utm_content=&utm_medium=email&utm_campaign=DailyHeadlines&utm_source=ST&eun=g721819d0r&userid=721819&email=amydugan2%40gmail.com&mu_id=5883165&utm_term=Daily